Author of

• 29777

  +

  S01 - IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening (Ticketed Session) (ID 96)

  • Event: WCLC 2019
  • Type: Symposium
  • Track: Screening and Early Detection
  • Presentations: 1
  • Now Available
  • Moderators:John Kirkpatrick Field, James L Mulshine
  • Coordinates: 9/07/2019, 07:00 - 12:00, Colorado Springs (1994)

  • 29796

    +

    S01.20 - How Will Success Will Be Judged (Now Available) (ID 3645)

    07:00 - 12:00  |  Author(s): Henry Marshall
    • Abstract
    • Presentation
    • Slides

    Abstract
    

    How will success be judged will vary according to the context of the evaluation.

    For instance, for a screening proponent, the implementation of a population based CT screening program may signify success, whereas the opposite conclusion will be drawn by those not swayed by the available evidence on lung cancer screening.

    From a technical viewpoint, as screening refers to the application of a test to a population which has no overt signs or symptoms of the disease in question, to detect disease at a stage when treatment is more effective. The technical effectiveness of CT screening can be viewed as its ability to detect the presence or absence of lung cancer, sensitivity, specificity, True and False positives, True and False negatives.

    From a CT screening program perspective, the metrics may include:

    · Participation (where it relates to an appropriate level of access and participation of people in the target and eligible population)

    · Cancer detection rates

    · Safety and harm minimisation (potential harm, either physical or emotional, is minimised)

    · Timeliness (providing access to screening and assessment services in a timely and efficient manner)

    · Client focused

    From an economic point of view, success may be a measure of the balance of the costs of screening (costs of the test and subsequent diagnostic tests and the costs associated with any hazard of the test as well as the costs of over-treatment) to reduced costs of therapy (costs associated with less expenditure on the treatment of the advanced disease, and the economic value of the additional years of life gained)

    For the policy maker, the metrics of success will include budgetary management, degree of realised benefit for the population targeted in the context of health care funding for other conditions (eg incidence and mortality), opportunity costs and population health measures, and adherence with their national screening policy

    Here we discuss the nuances of selecting metrics for lung cancer CT screening to inform our considerations for the multiple circumstances that make up the pragmatisim of real life.

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.